Evidence map›Paper›PMID 41870836›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2026

Targeting sialic acid metabolism: a therapeutic strategy against gastric cancer driven by WZ35.

Boxiang Hong, Ying Wang, Xinran Feng, Lihan Wei, Yichen Huang, Xiawei Zhang, Longyuchen Xu, Pinyan Jin, Liyuan Huang, Rui Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Boxiang Hong *Wenzhou Central Hospital, Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ying Wang *School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xinran Feng *The 2ⁿᵈ School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lihan WeiSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yichen HuangSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiawei ZhangSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Longyuchen XuSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Pinyan JinSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Liyuan HuangSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Rui LiSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xinyu WuRenji College, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhi LiRenji College, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Hangyu YeSchool of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Tongke Chen *Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, Zhejiang, China. dry136@163.com.
Xiaoyan Wang *The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. wxy669596rah@163.com.
Hao Zhang *Wenzhou Central Hospital, Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang, China. zhangchenxuan2017@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycolytic reprogramming is closely associated with the occurrence and progression of gastric cancer. Specifically, the energy derived from glucose metabolism and the cellular proteins by its intermediate products influence gastric cancer development. However, as an important branch of glucose metabolism, sialic acid metabolism and its mediated sialylation modifications remain insufficiently studied in gastric cancer, and their specific relationship with malignant tumor progression requires further exploration. This study employed a multi‑omics approach, integrating metabolomics, single‑cell RNA sequencing, and bulk RNA sequencing analyses, to investigate the metabolic landscape of gastric cancer and its associated alterations. The results indicated that sialic acid is a characteristic metabolite in malignant gastric cancer tissues. It modulates biological functions such as immune response, proliferative activity, and metabolic remodeling within gastric cancer tissues by influencing sialylation modifications. Furthermore, we identified the drug WZ35, which can inhibit the malignant proliferation of gastric cancer by targeting both sialic acid metabolism and sialylated protein modifications. We put forward a conjecture that the metabolism and modification of sialic acid promote the malignant development of gastric cancer, and we discovered that the drug WZ35 has an inhibitory effect on the sialic acid metabolism of gastric cancer.

Indexed as

N-Acetylneuraminic AcidStomach NeoplasmsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGlycosylationHumansMetabolic ReprogrammingN-Acetylneuraminic AcidGastric cancerGlycometabolismGlycosylationMulti-omics analysisSialic acidTumor metabolismWZ35

Identifiers

PMID41870836
PMCPMC13009457

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.